Flagship’s Cellarity maps out network-based drug discovery
Flagship launches Cellarity to deploy single cell technologies to find compounds that hit whole networks
Cellarity debuted Tuesday with technology to leverage single cell data to identify compounds that trigger protective changes in molecular networks, without needing to pin their therapeutic effects onto a single target.
With $50 million in funding from Flagship Pioneering, the company uses single cell technologies and machine learning to generate maps of disease-relevant molecular networks. The company’s more than 250 disease-focused “Cellarity Maps”